^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Endometrial Cancer |
| Drug: | prexasertib (ACR-368) (Chk2 inhibitor, Chk1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Acrivon Therapeutics Announces FDA Grants Fast Track Designation for Development of ACR-368 in Platinum-Resistant Ovarian Cancer and Endometrial Cancer
Published date:
05/09/2023
Excerpt:
Acrivon Therapeutics, Inc...announced that the company has been granted two Fast Track designations by the U.S. Food and Drug Administration (FDA) for the development of ACR-368 in platinum-resistant ovarian cancer and endometrial cancer...The second Fast Track development program designation was granted for the investigation of ACR-368 as a monotherapy treatment for patients with OncoSignature positive, recurrent high-grade endometrial cancer who have received at least two prior systemic treatment regimens.
Test:
